The preparation Sisen® contains recombinant human growth hormone (r-LHR), which stimulates the synthesis of protein and prevents its cleavage (catabolism), thereby affecting the growth and structure of the body. Pharmacodynamics Sayzen® is based on the interaction of the hormone with specific receptors of muscle cell cells (myocytes), liver cells (hepatocytes), fat cells (adipocytes), lymphocytes and hematopoietic bone marrow cells.
The drug helps to increase the level of peptide hormones of the hypothalamus (somatostatin and somatoliberin), which are secreted by the neurosecretory cells of the hypothalamus in the portal veins of the pituitary gland and act on growth hormone release cells (growth hormones). This causes an acceleration of growth (mainly due to the growth of long tubular bones of the limbs), contributes to the normalization of carbohydrate metabolism - the increase in the combustion of subcutaneous fat and the reduction of its deposition.
At the same time, the blood glucose (glycemia) and the level of endogenous secretion of insulin (C-peptide) remain within the physiological norm and can be significantly increased only if high doses of the drug are administered (20 mg).
In addition, somatotropin has an immunostimulatory effect on the growth of most internal organs and has a modulating effect on certain functions of the central nervous system.